Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 78

1.

Incorporating quality of evidence into decision analytic modeling.

Braithwaite RS, Roberts MS, Justice AC.

Ann Intern Med. 2007 Jan 16;146(2):133-41.

2.

Expanded HIV screening in the United States: effect on clinical outcomes, HIV transmission, and costs.

Paltiel AD, Walensky RP, Schackman BR, Seage GR 3rd, Mercincavage LM, Weinstein MC, Freedberg KA.

Ann Intern Med. 2006 Dec 5;145(11):797-806.

PMID:
17146064
3.
4.

Cost-effectiveness of captopril therapy after myocardial infarction.

Tsevat J, Duke D, Goldman L, Pfeffer MA, Lamas GA, Soukup JR, Kuntz KM, Lee TH.

J Am Coll Cardiol. 1995 Oct;26(4):914-9.

5.

Procedures and methods of benefit assessments for medicines in Germany.

Bekkering GE, Kleijnen J.

Eur J Health Econ. 2008 Nov;9 Suppl 1:5-29. doi: 10.1007/s10198-008-0122-5.

PMID:
18987905
6.
7.
8.

The cost effectiveness and cost utility of valsartan in chronic heart failure therapy in Italy: a probabilistic markov model.

Pradelli L, Iannazzo S, Zaniolo O.

Am J Cardiovasc Drugs. 2009;9(6):383-92. doi: 10.2165/11315730-000000000-00000.

PMID:
19929036
9.

Cost-effectiveness of screening for HIV in the era of highly active antiretroviral therapy.

Sanders GD, Bayoumi AM, Sundaram V, Bilir SP, Neukermans CP, Rydzak CE, Douglass LR, Lazzeroni LC, Holodniy M, Owens DK.

N Engl J Med. 2005 Feb 10;352(6):570-85.

10.

Cost-effectiveness of enfuvirtide in treatment-experienced patients with advanced HIV disease.

Sax PE, Losina E, Weinstein MC, Paltiel AD, Goldie SJ, Muccio TM, Kimmel AD, Zhang H, Freedberg KA, Walensky RP.

J Acquir Immune Defic Syndr. 2005 May 1;39(1):69-77.

PMID:
15851916
11.

Cost effectiveness of darunavir/ritonavir combination antiretroviral therapy for treatment-naive adults with HIV-1 infection in Canada.

Brogan AJ, Smets E, Mauskopf JA, Manuel SA, Adriaenssen I.

Pharmacoeconomics. 2014 Sep;32(9):903-17. doi: 10.1007/s40273-014-0173-7.

PMID:
24906477
12.

Comparison of Markov model and discrete-event simulation techniques for HIV.

Simpson KN, Strassburger A, Jones WJ, Dietz B, Rajagopalan R.

Pharmacoeconomics. 2009;27(2):159-65. doi: 10.2165/00019053-200927020-00006.

PMID:
19254048
13.

Cost-effectiveness of nucleoside reverse transcriptase inhibitor pairs in efavirenz-based regimens for treatment-naïve adults with HIV infection in the United States.

Brogan AJ, Talbird SE, Cohen C.

Value Health. 2011 Jul-Aug;14(5):657-64. doi: 10.1016/j.jval.2011.01.009. Epub 2011 Jun 12.

15.

Optimal frequency of CD4 cell count and HIV RNA monitoring prior to initiation of antiretroviral therapy in HIV-infected patients.

Kimmel AD, Goldie SJ, Walensky RP, Losina E, Weinstein MC, Paltiel AD, Zhang H, Freedberg KA; Cost-Effectiveness of Preventing AIDS Complications Investigators.

Antivir Ther. 2005;10(1):41-52.

PMID:
15751762
16.

Principles of good practice for decision analytic modeling in health-care evaluation: report of the ISPOR Task Force on Good Research Practices--Modeling Studies.

Weinstein MC, O'Brien B, Hornberger J, Jackson J, Johannesson M, McCabe C, Luce BR; ISPOR Task Force on Good Research Practices--Modeling Studies.

Value Health. 2003 Jan-Feb;6(1):9-17.

17.

US cost effectiveness of darunavir/ritonavir 600/100 mg bid in treatment-experienced, HIV-infected adults with evidence of protease inhibitor resistance included in the TITAN Trial.

Brogan A, Mauskopf J, Talbird SE, Smets E.

Pharmacoeconomics. 2010;28 Suppl 1:129-46. doi: 10.2165/11587490-000000000-00000.

PMID:
21182348
18.

Expanded screening for HIV in the United States--an analysis of cost-effectiveness.

Paltiel AD, Weinstein MC, Kimmel AD, Seage GR 3rd, Losina E, Zhang H, Freedberg KA, Walensky RP.

N Engl J Med. 2005 Feb 10;352(6):586-95.

19.

The clinical effectiveness and cost-effectiveness of cardiac resynchronisation (biventricular pacing) for heart failure: systematic review and economic model.

Fox M, Mealing S, Anderson R, Dean J, Stein K, Price A, Taylor RS.

Health Technol Assess. 2007 Nov;11(47):iii-iv, ix-248. Review.

20.

Cost-effectiveness of alternative strategies for the initial medical management of non-ST elevation acute coronary syndrome: systematic review and decision-analytical modelling.

Robinson M, Palmer S, Sculpher M, Philips Z, Ginnelly L, Bowens A, Golder S, Alfakih K, Bakhai A, Packham C, Cooper N, Abrams K, Eastwood A, Pearman A, Flather M, Gray D, Hall A.

Health Technol Assess. 2005 Jul;9(27):iii-iv, ix-xi, 1-158. Review.

Supplemental Content

Support Center